Biohaven Licenses MoDE IgG Degraders To Ono For Japan, South Korea, Taiwan And ASEAN For Up To $100M Near-Term Payments Including $80M Upfront; BHV-1300 In Phase 3 For Graves' Disease
Biohaven To Present Data On BHV-1530, FGFR3-Directed ADC Using Topoisomerase I Payload, At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
Warby Parker’s Unusual Options Activity Points to a Covered Call Bet: Bullish on Growth, Cautious on Valuation
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket